Growth Hormone Axis
This group spans the somatotropic axis as it is studied in the laboratory: GHRH analogs acting at the GHRH receptor, selective ghrelin-receptor (GHS-R1a) agonists, a C-terminal growth hormone fragment, and a long-acting IGF-1 analog studied downstream at the IGF-1 receptor. Research endpoints include receptor selectivity, pulsatile secretion patterns in animal models, IGFBP interaction, and Akt/mTOR pathway signaling.
Ipamorelin
5–10mg · COA published
Highly selective pentapeptide ghrelin receptor agonist, notable for minimal cross-activation of other pituitary axes.
- CAS
- 170851-70-4
- MW
- 711.85
- Purity
- Per published certificate
CJC-1295 (no DAC)
5–10mg · COA published
Modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation.
- CAS
- 863288-34-0
- MW
- 3367.9
- Purity
- Per published certificate
Tesamorelin
10–15mg · COA published
Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.
- CAS
- 218949-48-5
- MW
- 5135.86
- Purity
- Per published certificate
IGF-1 LR3
1mg · COA published
83-amino-acid IGF-1 analog engineered for markedly reduced binding to IGF binding proteins.
- CAS
- 946870-92-4
- MW
- 9117.6
- Purity
- Per published certificate
AOD-9604
5mg · COA published
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- Per published certificate
23
Certificates published
Published across 5 compoundsin this group, current and prior lots. Every certificate is issued by an independent laboratory and carries the issuing lab’s verification key, so each result can be checked with the laboratory directly.
Browse by research area
The same compounds, indexed by mechanism. Each area page lists everything in that category, not only the compounds studied for this goal.